Slides and webcasts from ESMO Virtual Plenaries are open to all ESMO Account holders, according to the presenters' agreement to release them.
Login and Watch now!
ESMO Virtual Plenary: December 2022
- Start date
- 15 Dec 2022
- End date
- 16 Dec 2022
- Location
- Virtual Meeting
The ESMO Virtual Plenaries are freely available to all healthcare professionals working in Oncology.
The use of these presentations is for personal educational purposes only. ESMO thanks the authors for their generosity.
An ad hoc interim overall survival results of niraparib with individualized starting dose as maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer (NORA): A double-blind, randomized, placebo-controlled, phase III trial
Thursday, 15 December 2022 |
Friday, 16 December 2022 |
|---|---|
18:30-19:30 CET |
13:00-14:10 CET |
Programme
Welcome and introduction, Scientific background and context An ad hoc interim overall survival results of niraparib with individualized starting dose as maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer (NORA): A double-blind, randomized, placebo-controlled, phase III trial Critical analysis and perspectives Discussion and Q&A (i) |
Programme
Virtual Plenary Expert Insights: Webcast of 15 December presentations, Discussion and Q&A (ii) Chair: Keiichi Fujiwara, Saitama Medical University International Medical Center, Saitama, Japan Mansoor Mirza, Rigshospitalet – Copenhagen University Hospital, Copenhagen, Denmark Antonio González-Martín, Clinica Universidad de Navarra, Madrid, Spain Aumkhae Sookprasert, Khonkaen University, Khonkaen, Thailand Hextan Yuen-Sheung Ngan, The University of Hong Kong Li Ka Shing Faculty of Medicine, Hong Kong, China Mastura MD Yusof, Pantai Hospital Kuala Lumpur, Kuala Lumpur, Malaysia |
